RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All Swissmedic updates
Swissmedic
REGULATORY UPDATE
Protection against designer drugs: Further psychoactive substances prohibited
Published: 3/13/2026Detected: 3/26/2026

Summary preview

Prohibits additional psychoactive substances to strengthen protections against designer drugs. The update likely expands the list of banned substances and may trigger compliance actions for products or ingredients…

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
safety
labeling
quality
#designer drugs
#psychoactive substances
#prohibition
#supply chain screening
#quality controls

Official Source Document
Source Verified

Access the original document directly from SWISSMEDIC.

View Official Document

More from Swissmedic

  • Extended deadline for publishing officially mandated information materials on the electronic publication platform11/12/2026
  • Designer drugs: FDHA brings further psychoactive substances under control11/10/2026
  • NAD+ supplements: When lifestyle products have criminal consequences11/9/2026
  • Publication eCTD v4.0 Implementation Guide Package v2.011/9/2026
  • Save the Date: Clinical Trials Symposium 202711/4/2026

Get Swissmedic alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service
  • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.